Variable levels of normal RNA in different fetal organs carrying a cystic fibrosis transmembrane conductance regulator splicing mutation

被引:30
|
作者
Chiba-Falek, O
Parad, RB
Kerem, E
Kerem, B [1 ]
机构
[1] Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Sch Med, Shaare Zedek Med Ctr, Dept Pediat, IL-91010 Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Sch Med, Shaare Zedek Med Ctr, Cyst Fibrosis Ctr, IL-91010 Jerusalem, Israel
[4] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA
关键词
D O I
10.1164/ajrccm.159.6.9808012
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Disease severity varies among cystic fibrosis (CF) patients carrying the same cystic fibrosis transmembrane conductance regulator (CFTR) genotype and among organs of the same individual. It has been shown that the class V splicing mutation 3849 + 10 kb C-->T produces both normal and aberrantly spliced CFTR transcripts. We analyzed the levels of normal CFTR messenger RNA (mRNA) in different organs of an aborted fetus carrying the 3849 + 10 kb C-->T mutation, and found that they correlated with the histopathologic changes observed in these organs. We performed semiquantitative nondifferential reverse transcription-polymerase chain reaction on several organs from a 22-wk aborted CF fetus carrying the 3849 + 10 kb C-->T mutation. A very low level (1%) of normal CFTR mRNA was detected in the severely affected ileum of this fetus. Higher levels were found in the histopathologically unaffected trachea (17%), colon (19%), and lung (26%). Thus, as early as in utero, the regulation of alternative splice-site selection is an important mechanism underlying variable CF severity. Understanding of the mechanisms regulating alternative splicing in different tissues will contribute to potential therapy for patients carrying splicing mutations in CF and other human disease genes.
引用
收藏
页码:1998 / 2002
页数:5
相关论文
共 50 条
  • [31] Cystic Fibrosis and Bone Disease: Defective Osteoblast Maturation with the F508del Mutation in Cystic Fibrosis Transmembrane Conductance Regulator
    Velard, Frederic
    Delion, Martial
    Le Henaff, Carole
    Guillaume, Christine
    Gangloff, Sophie
    Jacquot, Jacky
    Tabary, Olivier
    Touqui, Lhousseine
    Barthes, Francoise
    Sermet-Gaudelus, Isabelle
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189 (06) : 746 - 748
  • [32] Different activation mechanisms of cystic fibrosis transmembrane conductance regulator expressed in Xenopus laevis oocytes
    Weber, WM
    Segal, A
    Vankeerberghen, A
    Cassiman, JJ
    Van Driessche, W
    COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR AND INTEGRATIVE PHYSIOLOGY, 2001, 130 (03): : 521 - 531
  • [33] LOCALIZATION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MESSENGER-RNA IN HUMAN FETAL LUNG-TISSUE BY INSITU HYBRIDIZATION
    MCCRAY, PB
    WOHLFORDLENANE, CL
    SNYDER, JM
    JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (02): : 619 - 625
  • [34] Impact of Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutation on the Occurrence of Chronic Pancreatitis in Japanese Patients
    Aoyagi, H.
    Okada, T.
    Hasatani, K.
    Mibayashi, H.
    Hayashi, Y.
    Tsuji, S.
    Kaneko, Y.
    Yamagishi, M.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2009, 37 (02) : 378 - 384
  • [35] Cystic Fibrosis Transmembrane Conductance Regulator Intracellular Processing, Trafficking, and Opportunities for Mutation-Specific Treatment
    Rogan, Mark P.
    Stoltz, David A.
    Hornick, Douglas B.
    CHEST, 2011, 139 (06) : 1480 - 1490
  • [36] Mutation analysis of the CFTR (cystic fibrosis transmembrane conductance regulator) gene in korean pediatric patients with pancreatitis
    Jang, Jooyoung
    Kim, Kyungmo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 375 - 376
  • [37] Targeted Therapy for Cystic FibrosisCystic Fibrosis Transmembrane Conductance Regulator Mutation-Specific Pharmacologic Strategies
    Ronald C. Rubenstein
    Molecular Diagnosis & Therapy, 2006, 10 : 293 - 301
  • [38] Mutation-Specific Potency and Efficacy of Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Potentiators
    Caputo, Antonella
    Hinzpeter, Alexandre
    Caci, Emanuela
    Pedemonte, Nicoletta
    Arous, Nicole
    Di Duca, Marco
    Zegarra-Moran, Olga
    Fanen, Pascale
    Galietta, Luis J. V.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 330 (03): : 783 - 791
  • [39] A mutation in the cystic fibrosis transmembrane conductance regulator generates a novel internalization sequence and enhances endocytic rates
    Silvis, MR
    Picciano, JA
    Bertrand, C
    Weixel, K
    Bridges, RJ
    Bradbury, NA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (13) : 11554 - 11560
  • [40] REGULATION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE-TRANSCRIPTION AND ALTERNATIVE RNA SPLICING IN A MODEL OF DEVELOPING INTESTINAL EPITHELIUM
    MONTROSERAFIZADEH, C
    BLACKMON, DL
    HAMOSH, A
    OLIVA, MM
    HAWKINS, AL
    CURRISTIN, SM
    GRIFFIN, CA
    YANG, VW
    GUGGINO, WB
    CUTTING, GR
    MONTROSE, MH
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1992, 267 (27) : 19299 - 19305